FDA Warning Prompts Abbott to Halt Sale of Infant Probiotics
Abbott Laboratories will halt the sale of its Similac Probiotic Tri-Blend product for hospitalized preterm infants following a warning letter from the U.S. Food and Drug Administration (FDA). The FDA expressed concerns about the potential risks of fatal diseases or infections caused by bacteria or yeast in the probiotics. Infinant Health, a California-based company, received a similar warning in September and has since voluntarily recalled its product, Evivo with MCT Oil. The FDA is investigating reports of adverse events, including death, associated with these products and is working to obtain evidence and medical records.